To review the pharmacologic, pharmacokinetic, therapeutic, and safety aspects of irinotecan, a new antineoplastic agent, and to assess its role in the treatment of colorectal and lung cancer.
DATA SOURCES:
English-language articles from the MEDLINE database, January 1990–March 1998; Pharmacia & Upjohn Company; published articles and meeting abstracts.
STUDY SELECTION:
Studies in humans with cancer, clinical case reports, and open clinical studies were reviewed. Efficacy studies were limited to trials with at least 20 evaluable patients.
DATA EXTRACTION:
Relevant data were extracted from published reports and abstracts.
DATA SYNTHESIS:
Irinotecan is an effective agent for the treatment of advanced colorectal cancer. It demonstrates significant activity as a first-line agent and in patients with disease that is refractory to fluorouracil-containing regimens. Activity against lung cancer has also been demonstrated. Limited data indicate activity against cancers of the ovary, cervix, stomach, and in non-Hodgkin's lymphomas. Major toxicity consists of myelosuppression and diarrhea.
CONCLUSIONS:
Irinotecan is a useful addition to the antineoplastic drug family and offers significant efficacy for treatment of patients with fluorouracil-refractory colorectal cancer.
GottliebJAGuarinoAMCallJBOliverioVBlockJ. Preliminary pharmacokinetic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep1970;54: 461–70.
2.
SchaeppiVFleischmanRWCooneyDA. Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep1974;58: 25–36.
3.
TakimotoCHArbuckSG. The camptothecins. In: ChabnerBALongoDL, eds. Cancer chemotherapy and biotherapy. 2nd ed.Philadelphia: Lippincott-Raven, 1996: 463–84.
KawatoYAonumaMHirotaYKugaHSatoK. Intracellular role of SN-38, a metabolite of the camptothecin derivative, CPT-11, in the antitumor effect of CPT-11. Cancer Res1991;51: 4187–91.
6.
RowinskyEKGrochowLBEttingerDSSartoriusSELubejkoBGChenT-LPhase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl 1–1 0-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res1994;54:427–36.
7.
ChabotGGAbigergesDCatimelGCulineSdeForniMExtraJ-MPopulation pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials. Ann Oncol1995;6:1141–51.
8.
RothenbergMLKuhnJGBurrisHAIIINelsonJEckardtJRTristan-MoralesMPhase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol1993;11:2194–204.
9.
deForniMBugatRChabotGGCulineSExtraJ-MGouyetteAPhase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res1994;54:4347–54.
10.
OheYSasakiYShinkaiTEguchiKTamuraTKojimaAPhase I study and pharmacokinetics of CPT-11 with a 5-day continuous infusion. J Natl Cancer Inst1992;84:972–4.
11.
GuptaEMickRRamirezJWangXLestingiTMVokesEEPharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol1997;15:1502–10.
12.
AbigergesDChabotGGArmandJ-PHemitPGouyetteAGandiaD. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol1995;13: 210–21.
13.
CatimelGChabotGGGuastallaJPDumortierACoteCEngelCPhase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol1995;6:133–40.
14.
GuptaEWangXRamirezJRatainMJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol1997;39: 440–4.
15.
LokiecFCanalPGayCChatelutEArmandJ-PRocheHPharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol1995;36:79–82.
16.
ArmandJ-PExtraYMCatimelGAbigergesDMartyMClavelM. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for Phase II studies, as determined by European Phase I studies. Ann Oncol1996;7: 837–42.
LandisSHMurrayTBoldonSWingoPA. Cancer statistics 1998. CA Cancer J Clin1998;47: 6–29.
19.
CohenAMMinskyBDSchilskyRL. Cancer of the colon. In: DeVitaVTJrHellmanSRosenbergSA, eds. Cancer principles and practice of oncology. 5th ed.Philadelphia: Lippincott-Raven, 1997: 1144–97.
20.
PiedboisPBuyseMRustumYMachoveCErlichmanRWCarlsonFModulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol1993;10: 896–903.
21.
MachoverD. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer1997;80: 1179–87.
22.
RougierPBugatRPouillardJYCulineSSucEBrunetPPhase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapynaive patients and patients pre-treated with fluorouracil-based chemotherapy. J Clin Oncol1997;15:251–60.
23.
PitotHCWenderDO'ConnellMJSchroederGGoldbergRMRubinJA Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol1997;15:2910–9.
24.
ShimadaYRougierPPitotH. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer1996;32A(suppl 3):S13–7.
25.
RothenbergMLEckardtJRKuhnJGBurrisHAIIINelsonJHilsenbeckSGPhase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol1996;14:1128–35.
26.
ContiJAKemenyNESaltzLBHuangYTongWPChouT-CIrinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol1996;14:709–15.
27.
ShimadaYYoshinoMWakuiANakaoIFutatsukiKSakataYPhase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol1993;11:909–13.
28.
Von HoffDDRothenbergMLPitotHCElfringGLMohrlandJSSchaafLJIrinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): Overall results of FDA-reviewed pivotal US clinical trials (abstract). Proc Am Soc Clin Oncol1997;16:238a.
29.
SaltzLBKanowitzJKemenyNESchaafLSpriggsDStatonBAPhase I clinical and pharmacokinetic study of irinotecan, 5 fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol1996;14:2959–67.
30.
ShimadaYSasakiYSuganoKShiraoKKondoHYokotaTCombination Phase I study of CPT-11 (irinotecan) combined with continuous infusion 5 fluorouracil (5FU) in metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol1993;12:196.
31.
DucreuxMRougierPHYchouMSeltzJFBonnayMMignardPhase I/II study of escalating doses of CPT-11 in combination with LV5FU2 (“DeGramont” regimen) every two weeks in the treatment of colorectal cancer (CRC) after 5-FU failure (abstract). Proc Am Soc Clin Oncol1997;16:234a.
32.
YamatoTShimadaYShiraoKKondoHMatsumuraYSuganoKPhase I study of CPT-11 combined with sequential 5FU in metastatic colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol1996;15:481.
33.
BaroneCPozzoCStarkhammarHTerzoliEDinixLHmbletYCPT-11 alternating with 5-fluorouracil (5FU)/folinic acid (FA): A multicentre Phase II study in first-line chemotherapy (CT) of metastatic colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol1997;16:270a.
34.
RothenbergMLPazdurRRowinskyEKCohnALAlbertsDAPetitRGA Phase II multicenter trial of alternating cycle of irinotecan (CPT-11) and 5FU/LV in patients with previously untreated metastatic colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol1997;16:266a.
35.
GinsbergRJVokesEERabenA. Non-small cell lung cancer. In: DevitaVTJrHellmanSRosenbergSA, eds. Cancer principles and practice of oncology. 5th ed.Philadelphia: Lippincott-Raven, 1997: 858–911.
36.
FiglinRAHolmesERTumisiATIII. Neoplasms of the lung, pleura, and mediastinum. In: HaskellCM, ed. Cancer treatment. 4th ed.Philadelphia: Saunders, 1995: 385–413.
37.
NegoroSFukuokaMNiitaniHSuzukiANakabayashiTKimuraMA Phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother1991;18:1013–9, accessed in RothenbergML. CPT-11: An original spectrum of clinical activity. Semin Oncol1996;23 (suppl 3): 21–6.
38.
FukuokaMNiitaniHSuzukiAMonomiyaMHasegawaKNishiwakiYA Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol1992;10:16–20.
39.
BakerLKhanRLynchTSavarajNSandlerAFeunLPhase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol1997;16:461a.
40.
MoriKHiroseTMachidaSYokoyamaKTominagaK. A Phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur J Cancer1997;33: 503–5.
41.
MoriKSugaUKishiroIOhtaSTominagaK. A Phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol1994;13:366.
42.
MasudaNFukuokaMTakadaM. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol1992;10: 1775–80.
43.
MasudaNFukuokaMKudohSKusunokiYMatsuiKNakagawaKPhase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol1994;12:90–96.
44.
DeVoreRCrawfordJDimeryIEckardtJEckardtGKasunicDPhase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC (abstract). Proc Am Soc Clin Oncol1997;16:466a.
45.
MoriKHiroseTTominagaK. Phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol1997;16:476a.
46.
OshitaFNodaKNishiwakiYFujitaAKuritaYNakabayashiTPhase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer. J Clin Oncol1997;15:304–9.
47.
SakaHShimokataKYoshidaSNodaKNakaboyashiTTsuchiyaSIrinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): A Phase II study of Japan Clinical Oncology Group (JCOG 9504) (abstract). Proc Am Soc Clin Oncol1997;16:447a.
48.
MasudaNFukuokaMKushunokiYMatsuiKTakifujiNKudohSCPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol1992;10:1225–9.
49.
NegoroSFukuokaMNiitaniHTaguchiT. Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol1991;10:241.
50.
LeChevalierTIbrahimNChomyPRiviereAMonnierAMagheriniEA Phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) (abstract). Proc Am Soc Clin Oncol1997;16:450a.
51.
FujiwaraYYamakidoMFukuokaMKudohSFuruseKIkegamiHPhase I study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol1994;13:335.
52.
SugiyamaTNishidaTOokuraNYakushijiMIkedaMNodaKIs CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer (abstract)?Proc Am Soc Clin Oncol1997;16:378a.
53.
VerschraegenCFLevyTKudelkaAPLlerenaEEndesKFreedmanRPhase II study of irinotecan in prior chemotherapy treated squamous cell carcinoma of the cervix. J Clin Oncol1997;15:625–31.
54.
KambeMWakuiANakaoIFutasukiKSakataYYoshinoMA late Phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer (abstract). Proc Am Soc Clin Oncol1993;12:198.
55.
TsudaHTakatsukiKOhnoRMasaukaTOkadaKShirakawaSA late Phase II trial of a potent topoisomerase I inhibitor, CPT-11, in malignant lymphoma (abstract). Proc Am Soc Clin Oncol1992;11:316.
56.
RougierPBugatR. CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile. Semin Oncol1996;23 (suppl 3): 34–41.
57.
KudohSFukuokaMMasudaNYoshikawaAKusunokiYMatsuiKRelationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res1995;86:406–13.
58.
GuptaELestingiTMMickRRamirezJVokesEERatainMJ. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res1994;54: 3723–5.
59.
ArakiEIshikawaMIigoMKoideTItabashiMHoshiA. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res1993;84: 697–702.
60.
KaplanSAJackMLCotlerSAlexanderK. Utilization of area under the curve to elucidate the disposition of an extensively biotransformed drug. J Pharm Biopharm1973;1: 201–16.
61.
MickRGuptaEVokesEERatainMJ. Limited-sampling models for irinotecan pharmacokinetics—pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol1996;14: 2012–9.
62.
CanalPGayCDezeuzeADouillardJYBugatRBrunetRPharmacokinetics and pharmacodynamics of irinotecan during a Phase II clinical trial in colorectal cancer. J Clin Oncol1996;14:2688–95.
63.
1998 Drug topics red book. Montvale, NJ: Medical Economics Co., 1998:206,315,382.
64.
MoertelCG. Chemotherapy for colorectal cancer. N Engl J Med1994;330: 1136–42.
